Two Chinese Pharma Firms Report New Inhibitor Patents for Cancer Treatment
Two Chinese pharmaceutical companies have reported new inhibitor discoveries in recent patents. Changchun Genescience Pharmaceuticals identified FGFR2/3 inhibitors for cancer and bone disorder treatment, while Hengrui Pharmaceuticals disclosed new SNF2L2 inhibitors potentially useful for cancer therapy.
Two Chinese pharmaceutical companies have announced discoveries of new small-molecule inhibitors with potential applications in cancer treatment, according to recent patent reports.
Changchun Genescience Pharmaceuticals Co. Ltd. reported the discovery of salts of fibroblast growth factor receptor 2 (FGFR2) and/or fibroblast growth factor receptor 3 (FGFR3) inhibitors. The company stated these compounds are useful for the diagnosis and treatment of cancer, achondroplasia, and osteochondrodysplasia. The discovery was reported on June 12, 2026.
Separately, Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. described new probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors in a patent filed April 8, 2026. The companies indicated the inhibitors are potentially useful for the treatment of cancer.
FGFR2 and FGFR3 are receptor tyrosine kinases involved in cell growth and differentiation. Dysregulation of FGFR signaling has been implicated in various cancers. SNF2L2, also known as SMARCA2, is a component of the BAF chromatin-remodeling complex and plays a role in transcriptional regulation.